A new study published in the Journal of Biological Chemistry from UC Davis Comprehensive Cancer Center finds that TIGIT, an immune checkpoint receptor targeted by cancer immunotherapy drugs, triggers ...
Scientists discovered a new mechanism by which cancer cells evade the immune system to further their own agenda: invade, multiply, and spread. Identifying this mechanism has researchers hopeful that ...
Cellular regulatory mechanisms of TIGIT. TIGIT has the capacity to disrupt the CD226 cis-dimer structure or to competitively bind to CD155, thereby inhibiting cytotoxicity. TIGIT has also been ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results